The specific proteolytic activation steps of blood coagulation are catalyzed by serine proteinases that are homologous to each other and to the archetypal serine proteinases

Public Health Relevance

The formation of a blood clot results from a series of very specific activation steps in which an inactive precursor in blood is cleaved at specific sites to form an active product. Our research is directed towards obtaining new insights into how these reactions of high specificity occur. The findings will reveal novel strategies for interfering with these reactions and for the treatment of life-threatening blood clots associated with a variety of human diseases

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL074124-06A1
Application #
7663365
Study Section
Special Emphasis Panel (ZHL1-PPG-J (F2))
Project Start
2009-04-01
Project End
2014-03-31
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
6
Fiscal Year
2009
Total Cost
$490,348
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Thalji, Nabil K; Camire, Rodney M (2017) Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol 24:453-459
Vadivel, Kanagasabai; Kumar, Yogesh; Bunce, Matthew W et al. (2017) Interaction of factor V B-domain acidic region with its basic region and with TFPI/TFPI2: Structural insights from molecular modeling studies. Int Biol Rev 1:
Ostertag, Eric M; Bdeir, Khalil; Kacir, Stephen et al. (2016) ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. Transfusion 56:1775-85
Thalji, Nabil K; Ivanciu, Lacramioara; Davidson, Robert et al. (2016) A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med 22:924-32
Bradford, Harlan N; Krishnaswamy, Sriram (2016) The Fragment 1 Region of Prothrombin Facilitates the Favored Binding of Fragment 12 to Zymogen and Enforces Zymogen-like Character in the Proteinase. J Biol Chem 291:11114-23
Zheng, X Long (2015) ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 66:211-25
Baroni, M; Pavani, G; Pinotti, M et al. (2015) Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation. Biochim Biophys Acta 1854:1351-6
George, L A; Thalji, N K; Raffini, L J et al. (2015) Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L). J Thromb Haemost 13:1694-8
Lee, Manfai; Keener, Justin; Xiao, Juan et al. (2015) ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Cell Mol Life Sci 72:349-56
Ivanciu, Lacramioara; Camire, Rodney M (2015) Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. Blood 126:94-102

Showing the most recent 10 out of 101 publications